tradingkey.logo

Denali Therapeutics Announces Data Presentations On Enzyme Transportvehicle™ Programs For Hunter Syndrome, Sanfilippo Syndrome Type A And Pompe Disease At Upcoming 2026 Worldsymposium™

ReutersJan 29, 2026 9:02 PM

Denali Therapeutics Inc DNLI.O:

  • DENALI THERAPEUTICS ANNOUNCES DATA PRESENTATIONS ON ENZYME TRANSPORTVEHICLE™ PROGRAMS FOR HUNTER SYNDROME, SANFILIPPO SYNDROME TYPE A AND POMPE DISEASE AT UPCOMING 2026 WORLDSYMPOSIUM™

  • DENALI THERAPEUTICS INC: FDA DECISION ON TIVIDENOFUSP ALFA BLA EXPECTED BY APRIL 5, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI